Tesofensine (500 mcg), Oral
Increases availability of norepinephrine (energy/ alertness), dopamine (pleasure), and serotonin (mood) and decreases appetite. (28-32 pounds in 24 weeks) Human studies.
Turn-on the genes that promote weight loss. Produced overall 9.2% weight loss at 6 months in human trials. Good for decreasing appetite. Some insomnia, constipation, and nausea reported.
notes: Tesofensine decreases appetite while increasing the availability of norepinephrine (energy/alertness), dopamine (pleasure), and serotonin (mood). In human studies, weight loss of 13-14.4 kg (28-32 pounds) in 24 weeks was achieved.
Many people have trouble actually losing weight despite diet and exercise. Vie has products that may help and are listed below:
5 Amino-1MQ: Promotes fat breakdown by blocking NNMT. (7% loss of weight, 30 % loss of fat in 10 days) Mouse studies.
Amlexanox/TTA: Increases weight loss by activating genes. (2-10 pounds lost in 12 weeks without diet or exercise) Human studies.
Tesofensine: Increases availability of norepinephrine (energy/ alertness), dopamine (pleasure), and serotonin (mood) and decreases appetite. (28-32 pounds in 24 weeks) Human studies.
Tesamorelin: Increases GH secretion for visceral (intestine and liver) fat loss.(15.2% at 26 weeks) Human studies. FDA approved. 7 Keto DHEA: Weight loss without effort. Endorsed by Dr. Oz
Increases BMR,increases thyroid, and blocks cortisol. (6.6 pounds weight loss over 8 weeks) Human Studies.
methyl B-12: Improves mood, energy, and metabolism to promote weight loss. Safe and investigated by many human studies. Also helps with stress management. Commonly used in weight loss clinics.
MIC + mB12: The MIC amino acid combination is used at weight loss clinics to help your body eliminate fat when you diet and exercise.
GOAL: This 4 amino acid combination stimulates the body to increase its growth hormone secretion to improve your energy, build muscle, and decrease fat. This is commonly used at weight loss clinics to help patients lose weight.
Tesofensine, an inhibitor of pre-synaptic uptake of the neurotransmitters serotonin, noradrenaline and dopamine, acts primarily as an appetite suppressant with concomitant effects on fat oxidation and resting energy expenditure. Clinical trial data suggests it may have the potential to achieve greater reductions in weight to that seen with currently approved weight loss agents.
Efficacy demonstrated in early trials
Tesofensine has demonstrated evidence for efficacy in several Phase II trials. In the 203-patient TIPO-1 study, participants were prescribed an energy-restricted diet before randomisation to treatment with tesofensine 0.25mg (n=52), 0.5mg (n=50) or 1.0mg (n=49), or placebo (n=52) once daily for 24 weeks.
“Patients continuing with 0.5mg tesofensine achieved a total mean weight loss of 13–14kg at 24 weeks.”
At the end of the 24-week treatment period, tesofensine 0.25mg, 0.5mg and 1.0mg and diet induced a mean weight loss of 4.5%, 9.2% and 10.6% respectively. This compared with a mean weight loss of 2.0% for diet and placebo, a statistically significant difference (p<0·0001).
In the TIPO-4 trial, a 48-week open-label extension to the TIPO-1 trial, preliminary results suggest that weight loss with tesofensine is sustained. After an initial eight-week washout period, patients continuing with 0.5mg tesofensine achieved a total mean weight loss of 13–14kg at 24 weeks.
Additionally, previous placebo recipients switched to tesofensine 0.5mg lost approximately 9kg over the same period.
Dose-dependent adverse gastrointestinal effects were observed with tesofensine in the clinical trials in addition to increases in blood pressure and heart.
However, at the anticipated therapeutic dose of 0.5mg, discontinuations for adverse effects with tesofensine were similar to placebo (8%).
In TIPO-2, 32 obese patients with their BMI values ranging from 28 to 35 were enrolled and treated for a period of 14 days.
Patients were administered either Tesofensine or a placebo. The drug reduced the desire to eat and the satiety levels were found to be increased.